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Paraoxonase (PON), a high-density lipoprotein–associated enzyme, is believed to protect against low-density li-
poprotein oxidation and thus affects the risk of coronary artery disease (CAD). Three polymorphisms in the PON1
(Leu55Met and Gln192Arg) and PON2 (Ser311Cys) genes have been shown to be associated with the risk of CAD
in several European or European-derived populations. In the present study, we examined the associations between
these three markers and the severity of CAD as determined by the number of diseased coronary artery vessels in
711 subjects (589 whites and 122 blacks) from the Women’s Ischemia Syndrome Evaluation (WISE) study. WISE
is a National Heart, Lung, and Blood Institute–sponsored multicenter study designed to address issues related to
ischemic-heart-disease recognition and diagnosis in women. Subjects were classified as having normal/minimal CAD
(!20% stenosis), mild CAD (20%–49% stenosis), and significant CAD (50% stenosis). The women who had
50% stenosis were further classified into groups with one-, two-, or three-vessel disease if any of the three coronary
arteries had diameter stenosis 50%. No significant association was found between the PON polymorphisms and
stenosis severity in either white or black women. However, among white women, when data were stratified by the
number of diseased vessels, the frequency of the PON1 codon 192 Arg/Arg genotype was significantly higher in
the group with three-vessel disease than in the other groups (those with one-vessel and two-vessel disease) combined
(17.02% vs. 4.58%; ). Similarly, the frequency of the PON2 codon 311 Cys/Cys genotype was signif-Pp .0066
icantly higher in the group with three-vessel disease than in the other groups combined (15.22% vs. 4.61%;
). The adjusted odds ratios for the development of three-vessel disease were 2.80 (95% confidence intervalPp .018
1.06–7.37; ) for PON1 codon 192 Arg/Arg and 3.68 (95% confidence interval 1.26–10.68; )Pp .038 Pp .017
for PON2 codon 311 Cys/Cys. Our data indicate that the severity of CAD, in terms of the number of diseased
vessels, may be affected by common genetic variation in the PON gene cluster, on chromosome 7.
Introduction
Coronary artery disease (CAD) is a major cause of
mortality and morbidity in developed countries. The
oxidative modification of low-density lipoprotein (LDL)
is an important element in the development of athero-
sclerosis (Navab et al. 1996). Numerous studies sug-
gest that oxidative modification of LDL initiates the
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development, in the arterial wall, of foam cell–laden
fatty streaks, believed to cause atherosclerosis. Recent
evidence suggests that high-density lipoprotein (HDL)
inhibits the oxidation of LDL and thus may provide
protection against the risk of CAD (M. I. Mackness
and Durrington 1995; Navab et al. 2000). Serum para-
oxonase (PON1), an HDL-associated enzyme, has been
shown to be responsible for this antioxidative property
of HDL (Watson et al. 1995). PON1 is a 44-kDa Ca2-
dependent enzyme that remains associated with apo-
lipoprotein (apo) A-I and apoJ on HDL (Blatter et al.
1993; Kelso et al. 1994). PON1 can hydrolyze a variety
of substrates; is involved in the detoxification, in the
P-450 system, of organophosphate insecticides such
as parathion, chlorpyrifos, and diazinon; and protects
against the nerve agents soman and sarin (M. I. Mack-
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ness et al. 1991, 1993; M. I. Mackness and Durrington
1995; Shih et al. 1998). PON1 (MIM 168820)—along
with two homologous genes, PON2 (MIM 602447)
and PON3 (MIM 602720)—is located on chromosome
7q21.3-22.1 (Primo-Parmo et al. 1996). Recently, it has
been shown that the rabbit (Draganov et al. 2000) and
human (Reddy et al. 2001) PON3 enzymes are also
associated with HDL and that human PON3 has bi-
ological activity similar to that of PON1 (Reddy et al.
2001). PON2 also has antioxidant properties and is
capable of preventing the peroxidation of LDL, but,
unlike PON1 and PON3, PON2 is not associated with
HDL and may only exert its antioxidant function at
the cellular level (Ng et al. 2001). Three genetic poly-
morphisms in the PON1 (Leu55Met and Gln192Arg)
and PON2 (Ser311Cys) genes have been reported to
be associated with the risk of CAD in many (Ruiz et
al. 1995; Odawara et al. 1997; Sanghera et al. 1997,
1998a; Zama et al. 1997) but not all (Ko et al. 1998;
Ombres et al. 1998; Aynacioglu and Kepekci 2000;
Gardemann et al. 2000; Imai et al. 2000) studies.
CAD is the leading cause of death in women in
the United States. The Women’s Ischemia Syndrome
Evaluation (WISE) study is a National Heart, Lung,
and Blood Institute (NHLBI)–sponsored, four-center
study designed to explore mechanisms and genetic
backgrounds for CAD among women and to im-
prove the disease recognition, diagnosis, and treat-
ment (Merz et al. 1999). As part of the WISE study,
each subject underwent diagnostic quantitative cor-
onary angiography, to assess CAD severity. The aim
of the present study was to investigate the associa-
tion between severity of the disease and variation in




Women 18 years of age were enrolled in the WISE
study if they met all of the following criteria: (1) chest
pain or other symptoms suggestive of myocardial ische-
mia, (2) clinically indicated coronary angiography, and
(3) ability to give informed written consent. All patients
underwent the clinical examination at one of four clinical
centers (University of Alabama at Birmingham, Allegheny
University of the Health Sciences at Pittsburgh, University
of Florida at Gainesville, and University of Pittsburgh).
Major exclusion criteria were as follows: pregnancy, car-
diomyopathy, contraindications to provocativediagnostic
testing, New York Heart Association class IV congestive
heart failure, recent myocardial infarction, significant
valvular or congenital heart disease, and recent coro-
nary angioplasty or coronary bypass surgery. A total
of 8,544 women were evaluated, of whom 1,903 (22%)
were eligible for study entry. For the present study, DNA
samples were available from 711 of the 941 (49% of
eligible) women who were finally enrolled. In the present
study, 589 were white (non-Hispanic) women, and 122
were black or African American women (not of Hispanic
origin), with a mean age of 58 years. Homogeneity tests
using genotype data showed no statistically significant
difference between the four clinical sites from three geo-
graphic locations for whites (346 from Pennsylvania,
121 from Alabama, and 122 from Florida) and blacks
(31 from Pennsylvania, 58 from Alabama, and 33 from
Florida) separately. Thus, white and black subjects were
pooled separately, and the data were analyzed by ethnic
groups.
CADwasmeasured for all women by quantitative coro-
nary angiography. In addition, atherosclerotic risk factors
were assessed—including lipid, sex hormone, and homo-
cysteine levels; brachial artery endothelial function; and
demographic and psychosocial profiles (Merz et al. 1999).
Lipid samples were analyzed by the lipid core labora-
tory at the Cedars Sinai Medical Center, which is enrolled
in the Centers for Disease Control and Prevention lipid-
standardization program (Bittner et al. 2000). Fasting to-
tal plasma cholesterol, triglycerides, andHDL-cholesterol
levels were determined by enzymatic assays, as described
elsewhere (Lipid Research Clinics Program 1974). LDL
cholesterol was calculated using the Friedewald equation
(Friedewald et al. 1972). The coefficients of variation for
total cholesterol, HDL cholesterol, and triglycerides were
1.80%, 1.23%, and 3.93%, respectively (Bittner et al.
2000).
Quantitative coronary angiography was performed
using the WISE study protocol, and the data were an-
alyzed at the angiography core laboratory at Brown
University by investigators blinded to subject identifi-
ers. Luminal diameter was measured at all stenoses and
at nearby reference segments by using an electronic cine-
projector–based “crosshair” technique (Vanguard Instru-
ment) (Sharaf et al. 1997). Enrolled patients were clas-
sified into three groups: normal/minimal CAD (!20%
stenosis), mild CAD (20%–49% stenosis), and significant
CAD (50% stenosis). Patients with significant CAD
were further stratified into groups with one-, two-, or
three-vessel disease, as determined by the number of ar-
teries having 50% stenosis.
Genetic Polymorphism Detection
Genomic DNA was isolated by the Puregene Systems
DNA purification kit (Gentra). Standard PCR protocols,
followed by restriction-enzyme digestions, were used to
screen the three PON polymorphisms, as described else-
where (Humbert et al. 1993; Sanghera et al. 1997, 1998a).
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Size fractionations for all three polymorphisms were per-
formed in 3% Nusieve (FMC) and 1% agarose gel.
Statistical Analyses
Among different patient groups, one-way analysis of
variance was used to test for mean differences in lipid
traits and continuous variables (e.g., age and BMI). For
discrete variables, possible differences in proportionswere
compared among different groups with CAD by using
Pearson x2 tests. These descriptive statistical analyseswere
performed with SPSS (version 10.0 for Windows).
All analyses of the relationships between PON geno-
types and CAD-related measures were performed sepa-
rately in white and black women. Allele frequencies were
calculated by allele counting, and deviations of the ob-
served genotype frequencies from Hardy-Weinberg equi-
librium were identified by x2 test. Genotype-frequency
differences among groups with different CAD severity
were compared using a x2 test for a contingency2 # k
table and a x2 test for trends (Newman 2001, pp. 115–
117). Specifically, in the trend test, we assigned CAD-
severity levels of 1, 2, and 5, to represent the groups with
!20% stenosis, 20%–49% stenosis, and50% stenosis,
respectively, and 1, 2, and 3, to represent the groups with
one-, two-, and three-vessel disease, respectively. The dif-
ferences in allele frequencies between two different CAD-
severity diseased groups and between racial groups were
estimated using a standard Z test. The relationships be-
tween three PON polymorphisms and the number of
diseased vessels were further determined by logistic-re-
gression analyses using R software (version 1.2.1) (Ihaka
1996). Adjusted odds ratios (ORs) and 95% CIs of the
genotype-disease association were estimated after ad-
justing for known coronary risk factors, including age,
BMI, smoking history, alcohol use, family history of
CAD, history of hypertension, history of diabetes, men-
opausal status, lipid-lowering–drug (statins/other) in-
take, and lipid profile. Except for age, BMI, and lipid
profile, which were continuous variables, all variables
entered in the regression model were discrete variables.
We also investigated whether the PON gene haplo-
types were associated with an increasing number of dis-
eased vessels. Linkage disequilibrium among the three
markers was estimated by the EH (estimate haplotype
frequencies) program (version 1.2) (Xie and Ott 1993),
which uses the expectation-maximization algorithm to
obtain maximum-likelihood estimates of the haplotype
frequencies. To test whether the estimated haplotype fre-
quencies differed between the individuals with three-ves-
sel disease and the individuals with no-vessel disease, we
used a nonparametric T5 statistic, as implemented in the
EH program; the T5 statistic is approximately distrib-
uted as a x2 (Zhao et al. 2000; Tsai et al. 2001).
Results
Distribution of Clinical Characteristics of the Study
Subjects in Relation to the Severity of CAD
Table 1 shows the distributions of age, BMI, smoking
history, alcohol use, menopausal status, and medical
history, along with quantitative lipid levels, by the num-
ber of diseased vessels for white women. Age ( ),P ! .001
history of hypertension ( ), history of diabetesPp .024
(P ! .001), and lipid-lowering–drug (statins) intake
( ) were significantly associated with the num-P ! 0.001
ber of diseased vessels, and plasma HDL-cholesterol lev-
els ( ) were inversely related to the severity ofPp .023
CAD. Total plasma cholesterol and LDL-cholesterol
levels did not show any significant differences among
groups with different numbers of diseased vessels. Be-
cause of the small total number of black women, we did
not have enough individuals in each category based on
the number of diseased vessels (i.e., 72 had no-vessel
disease, 21 had one-vessel disease, 10 had two-vessel
disease, and 8 had three-vessel disease) to obtain mean-
ingful results when using this characteristic.
PON Polymorphisms among Whites and Blacks
The allele and genotype distributions of three PON
polymorphisms, stratified by race, are shown in table 2.
The genotype distributions of the three polymorphisms
were in Hardy-Weinberg equilibrium within all sub-
groups. The distributions of all three polymorphismswere
significantly different between whites and blacks. The
PON1Met55 allele frequency was significantly higher in
whites than in blacks (0.375 vs. 0.193; ),P ! .0001
whereas frequencies of the PON1 Arg192 (0.295 vs.
0.631; ) and PON2 Cys311 (0.239 vs. 0.311;P ! .00001
) alleles were lower in whites than in blacks.Pp .0264
Association between PON Polymorphisms
and the Severity of CAD
No significant association was observed between the
three PON polymorphisms and stenosis severity in either
white or black women (data not shown). However, when
we stratified the patients with50% stenosis into groups
with one-, two-, or three-vessel disease, significant asso-
ciations were noted between the PON1 codon 192 and
PON2 codon 311 polymorphisms and the number of
diseased vessels in whites but not in blacks (table 3). The
frequency of the Arg/Arg genotype of the PON1 codon
192 polymorphism was significantly higher among the
patients with50% stenosis in all three arteries (17.02%)
compared with patients with one (7.69%) and two (0%)
diseased vessels ( ). Similarly, the frequency ofPp .0066
the PON2 codon 311 Cys/Cys genotype was significantly
higher in the group with three-vessel disease (15.2%)
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Table 1
Patient Characteristics According to the Number of Diseased Vessels in Whites
CHARACTERISTIC










Age (years) 55.2  .6 63.2  1.5 61.2  1.5 64.9  1.5 !.001
BMI (kg/m2) 29.2  .4 28.5  .7 29.1  .9 29.1  .9 .826
Former smoker (%) 31.3 46.2 28.3 38.3 .247
Current smoker (%) 20.2 16.7 24.5 17 …
Alcohol use within past 6 mo (yes, %) 15.9 14.5 13.2 4.3 .214
Family history of CAD (yes, %) 68.7 64.5 76.9 61.7 .353
History of hypertension (yes, %) 49.4 57.7 65.4 67.4 .024
History of diabetes (yes, %) 11.7 25.6 35.8 46.8 !.001
Menopause (yes, %) 79.1 85.7 88.7 91.3 .072
Lipid-lowering–drug use:
Statins (yes, %) 18.7 33.3 34.0 46.8 !.001
Others (yes, %) 4.2 9.0 1.9 4.3 .49
Total cholesterol (mg/dl) 198  2.4 191  4.8 198  6.6 197  6.6 .694
Triglycerides (mg/dl) 158  7.3 169  10.2 177  11.7 169  15.2 .677
HDL cholesterol (mg/dl) 55  .7 52  1.4 50  1.3 50  1.9 .023
LDL cholesterol (mg/dl) 114  2.1 106  4.4 112  6.0 116  6.2 .367
Table 2
PON Genotype and Allele Distribution in Whites and Blacks
Whites Blacks P
PON1 codon 55:
Leu/Leu 227 (38.5%) 80 (65.6%)
Leu/Met 282 (47.9%) 37 (30.3%)
Met/Met 80 (13.6%) 5 (4.1%)
Total 589 122
Met allele .375 .193 !.0001
PON1 codon 192:
Gln/Gln 293 (49.7%) 19 (15.6%)
Gln/Arg 245 (41.6%) 52 (42.6%)
Arg/Arg 51 (8.7%) 51 (41.8%)
Total 589 122
Arg allele .295 .631 !.00001
PON2 codon 311:
Ser/Ser 343 (58.2%) 57 (47.9%)
Ser/Cys 210 (35.7%) 50 (42.0%)
Cys/Cys 36 (6.1%) 12 (10.1%)
Total 589 119
Cys allele .239 .311 .0264
compared with patients in the groups with one-vessel
(3.9%) and two-vessel (5.7%) disease ( ). The x2Pp .018
test for trends showed a significant association with an
increasing number of diseased vessels for the PON2 co-
don 311 polymorphism ( ; ) but not2x p 4.89 Pp .027
for PON1 codon 192 ( ; ).2x p 2.26 Pp .13
Given that age, BMI, smoking, alcohol use, meno-
pausal status, medical history, lipid-lowering–drug use,
and lipid profile are possible risk factors for CAD, lo-
gistic-regression models were used to evaluate the in-
dependence of the positive associations between CAD
severity, in terms of the number of diseased vessels, and
the PON1 codon 192 and PON2 codon 311 polymor-
phisms. The adjusted OR between the PON1 codon 192
Arg/Arg genotype versus the PON1Gln192 allele carriers
(Gln/Gln plus Gln/Arg genotypes) was 2.80 (95% CI
1.06–7.37; ) for the presence of three-vesselPp .038
disease. The adjusted OR for PON2 codon 311 Cys/Cys
genotype versus PON2 Ser311 allele carriers (Ser/Ser
plus Cys/Ser genotypes) was 3.68 (95% CI 1.26–10.68;
) for the presence of three-vessel disease.Pp .017
Haplotype Analyses
The pairwise measure of linkage disequilibrium,
, is reported in table 4. A value of 1 indicates′ ′FD F FD F
complete linkage disequilibrium between two markers.
Among white women, significant linkage disequilibrium
was observed between PON1 codon 55 and PON1 co-
don 192, as well as between PON1 codon 55 and PON2
codon 311. In the sample of black women whom we
studied, the PON2 codon 311 polymorphism was in
significant linkage disequilibrium with both the PON1
codon 55 ( ) and PON1 codon 192 ( )Pp .03 Pp .025
polymorphisms.
The estimated haplotype distribution for all three sites
in white women is shown in table 5. As can be seen in
table 6, the overall estimated haplotype frequencies of
PON1 codon 55, PON1 codon 192, and PON2 codon
311 were significantly different between case subjects
(individuals with three-vessel disease) and control sub-
jects (individuals with no-vessel disease) ( ). InPp .012
particular, the estimated frequency of the Leu-Gln-Ser
(15.4% vs. 24.4%; ) haplotype was signifi-Pp .026
cantly higher in the control group than in the case (i.e.,
three-vessel disease) group. However, the frequency of
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Table 3
PON1 Codon 55, PON1 Codon 192, and PON2 Codon 311 Polymorphisms
by Number of Diseased Vessels in Whites




Leu/Leu 34 (43.59%) 20 (37.74%) 13 (27.66%)
Leu/Met 33 (42.31%) 25 (47.17%) 26 (55.32%)
Met/Met 11 (14.10%) 8 (15.09%) 8 (17.02%)
Total 78 53 47 2x p .19
Met allele .353 .387 .447 Pp .67
PON1 codon 192:
Gln/Gln 37 (47.44%) 28 (52.83%) 20 (42.55%)
Gln/Arg 35 (44.87%) 25 (47.17%) 19 (40.43%)
Arg/Arg* 6 (7.69%) 0 8 (17.02%)
Total 78 53 47 2x p 2.26
Arg allele .301 .236 .372 Pp .13
PON2 codon 311:
Ser/Ser 48 (62.34%) 31 (58.49%) 26 (56.52%)
Ser/Cys 26 (33.77%) 19 (35.85%) 13 (28.26%)
Cys/Cys** 3 (3.90%) 3 (5.66%) 7 (15.22%)
Total 77 53 46 2x p 4.89
Cys allele .208 .236 .293 Pp .027
a Performed among three groups with stenosis: PON1 codon 55 (Met/Met vs.
Leu/Leu plus Leu/Met), PON1 codon 192 (Arg/Arg vs. Gln/Gln plus Gln/Arg),
and PON2 codon 311 (Cys/Cys vs. Ser/Ser plus Ser/Cys).
* , between the group with three-vessel disease and the groups withPp .0066
one-vessel and two-vessel disease (x2 test).
** , between the group with three-vessel disease and the groups withPp .018
one-vessel and two-vessel disease (x2 test).
Table 4
Pairwise Measure of Linkage Disequilibrium, ,′FDF







′FDF Pa ′FDF Pa
PON1 codon 55 vs.
PON1 codon 192 .594 .000 .168 .068
PON1 codon 55 vs.
PON2 codon 311 .303 .000 .429 .026
PON1 codon 192 vs.
PON2 codon 311 .002 .941 .293 .025
a Obtained by x2 tests.
the Met-Gln-Cys haplotype was significantly higher in
case subjects (15.5%) than in control subjects (4.2%)
( ). Again, because of the small sample size, wePp .003
did not perform the similar analyses on black women.
Gene-Environment Interaction
As a multifactorial disease, CAD is caused by inter-
actions between environmental and genetic factors.
Therefore, we performed a series of exploratory logis-
tic-regression analyses, to test for possible interactions
between the PON polymorphisms and other factors.
Interaction between the PON genotype and one risk
factor at a time was tested in the logistic-regression
model. Two marginally significant interactions were
found between PON1 codon 192 polymorphism and
BMI (OR 1.2; 95% CI 1.0–1.5; ) and betweenPp .05
PON2 codon 311 and HDL-cholesterol level (OR 0.93;
95% CI 0.87–0.99; ). However, consideringPp .03
that, in total, 27 comparisons were analyzed, these two
findings are provisional and need to be explored and
replicated.
Discussion
The oxidative damage to vital biological systems can lead
to enhanced expression of inflammatory genes that ul-
timately contribute to the development of several chronic
diseases, including CAD, cancer, and diabetes (Navab et
al. 1996; Papas 1996), and that contribute to aging
(Martin et al. 1996). The balance between oxidants and
antioxidants basically affects all biological systems and,
ultimately, the clinical course. The oxidation of LDL and
its involvement in the development of foam cell–laden
fatty streaks in the arterial wall are believed to initiate
the atherosclerotic process (Steinberg et al. 1989; Witz-
tum and Steinberg 1991). In vitro studies indicate that
HDL-associated PON1 prevents LDL oxidation (Aviram
et al. 1998) and can destroy biologically active lipids in
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Table 5
















Leu Gln Cys 8.8 5.5 9.6 .114
Leu Gln Ser 23.7 15.4 24.4 .026
Leu Arg Cys 9.6 8.8 9.8 .764
Leu Arg Ser 19.1 25.7 18.1 .110
Met Gln Cys 6.0 15.5 4.2 .003
Met Gln Ser 31.4 26.4 32.5 .211
Met Arg Cys .4 .0 .5 .056
Met Arg Ser 1.2 2.8 .8 .263
a Obtained from Z tests, to compare haplotype frequencies between the groups with three-
vessel and no-vessel disease.
Table 6
Association Testing Based on the Haplotype Frequencies
in White Women
Group n ln(L) x2 Pa
Case (three-vessel disease) 47 131.29 23.49 .012
Control (no-vessel disease) 349 908.85 100.07
Combination 396 1,049.18 110.8
a Calculated from the T5 statistic: 2[  ln (L) ln (L)case control
; .ln (L) dfp 7casecontrol
mildly oxidized LDL (Watson et al. 1995), and PON1
may thus affect the process of atherosclerosis. Further
evidence that PON is directly involved in the process of
atherosclerosis comes from inbred strains of mice (Shih
et al. 1996) and PON1-knockout mice (Shih et al. 1998).
PON1 has also been localized in the normal human ar-
terial wall, and its concentration increases significantly
as atherosclerosis progresses, possibly as a result of ox-
idative stress that may overwhelm and retain HDL in
the lesions and thus may increase PON concentration
(M. I. Mackness et al. 1997). Recently, it has also been
demonstrated that PON1 has the capacity to reduce ox-
idized lipids in human atherosclerotic lesions derived from
either coronary artery or carotid specimens (Aviram et al.
2000). Because of the convincing in vitro and in vivo data
that implicate PON in the prevention of LDL oxidation
and because of the potentially important role that PON
genetic variation plays in affecting the risk of CAD, Hei-
necke and Lusis (1998) have advocated adding the PON
locus to a short list of genes that are involved in common
forms of CAD. Numerous studies conducted in a case-
control design have shown the association between the
PON1 Arg192 allele and the increased risk of CAD
(Ruiz et al. 1995; Odawara et al. 1997; Sanghera et al.
1997; Zama et al. 1997), although the results have not
been consistent across studies (Ko et al. 1998; Ombres
et al. 1998; Aynacioglu and Kepekci 2000; Gardemann
et al. 2000; Imai et al. 2000).
To our knowledge, no study has evaluated the role
that PON polymorphisms play in the severity of CAD
or whether the distributions of PON polymorphisms
vary between whites and blacks. The present study was
designed to address these two questions in women with
chest pain or suspected myocardial ischemia. The results
of the present study may improve the disease recogni-
tion, diagnosis, and treatment. On the basis of the se-
verity of the disease, the subjects were divided into three
groups: !20% stenosis, 20%–49% stenosis, and50%
stenosis. Furthermore, the patients with significant dis-
ease (50% stenosis) were stratified as having one-,
two-, or three-vessel disease. Although this selected group
of subjects is different from the general population, it is
representative of patients evaluated for chest pain and,
on the basis of its clinical data, also constitutes a good
study population for studying the disease severity. The
distribution of PON alleles in the group with no disease
is very similar to those found in several other unaffected
control groups (Garin et al. 1997; B. M. Mackness et al.
2001; Sentı´ et al. 2001; Topic et al. 2001), and the
strength of our genetic association results is comparable
to reported case-control studies for PON. These obser-
vations indicate that a possible bias caused by the inclu-
sion of an angiographic case-control cohort (Fried and
Pearson 1987; Pearson and Derby 1991; Reed and Yano
1991) may not have affected the outcome of the pres-
ent study.
We examined two polymorphisms in the PON1 gene
(Leu55Met and Gln192Arg) and one polymorphism in
the PON2 gene (Ser311Cys). The distributions of all
three polymorphisms were significantly different between
white and black women. Whereas the frequency of the
PON1 Met55 allele was higher in whites than blacks
(0.375 vs. 0.193; ), the reverse was true for theP ! .0001
frequencies of the PON1 Arg192 allele (0.631 vs. 0.295;
) and thePON2Cys311 allele (0.311 vs. 0.239;P ! .0001
). Previously, the lowest frequency of thePp .0264
PON1Met55 allele had been reported in Chinese (3.6%)
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(Sanghera et al. 1998b), indicating a significant difference
in the occurrence of this allele among three major racial
groups. The relatively high frequency of the PON1
Arg192 allele in blacks is similar to that reported pre-
viously in Chinese and Japanese, varying from 58% to
65% (Odawara et al. 1997; Sanghera et al. 1997; Zama
et al. 1997; Ko et al. 1998; Imai et al. 2000).
The present sample of black women was very small;
therefore, we did not perform analyses of CAD severity
on the black sample, because such analyses would not
be meaningful. Among white women, we did not ob-
serve any significant association between the three PON
polymorphisms and stenosis severity; however, the
PON1 Gln192Arg and PON2 Ser311Cys polymor-
phisms showed significant association with the severity
of disease on the basis of the number of diseased vessels,
as measured by quantitative coronary angiography. The
frequencies of both the Arg192 allele (0.372 vs. 0.275;
) and the Arg/Arg genotype (17% vs. 4.58%;Pp .07
) of the PON1 Gln192Arg polymorphismPp .0066
were higher in the group with three-vessel disease than
in the groups with other numbers of diseased vessels.
The adjusted OR associated with the Arg/Arg genotype
was 2.80, similar to that reported in several other case-
control studies, which also found positive association of
the Arg192 allele with CAD risk (Ruiz et al. 1995; Oda-
wara et al. 1997; Sanghera et al. 1997, 1998a; Zama et
al. 1997; Imai et al. 2000). However, a number of other
studies have reported no association between the Arg192
allele and CAD risk (Ko et al. 1998; Ombres et al. 1998;
Aynacioglu and Kepekci 2000; Gardemann et al. 2000),
a dilemma reflected in many association studies. A recent
meta-analysis of 18 studies has confirmed the hypothesis
that the PON1 Arg192 allele is a risk factor for CAD
(Durrington et al. 2001). Because association studies are
subjected to several biases, further support of this hy-
pothesis could be provided by the performance of func-
tional studies. Because PON1 inhibits LDL oxidation, we
expect that the Arg192 allele would be associated with
less protection against the oxidativemodification of LDL.
Indeed, in vitro functional data show that the Arg192
allele is less efficient at protecting LDL from oxidation
(Aviram et al. 1998; B. M. Mackness et al. 1998). The
functional data, together with the association studies,
strongly support the notion that the Arg192 allele of the
PON1 codon 192 polymorphism may be functional in
vivo. Some recent studies have suggested that the PON
activity or concentration, in addition to the PON ge-
notype, should be included, to fully understand their joint
contribution to the risk of CAD (Richter and Furlong
1999; Jarvik et al. 2000; B. M. Mackness et al. 2001).
However, PON activity or concentration data were not
available in the WISE cohort, so we were unable to ex-
plore this aspect.
Previously, the PON2 Ser311 allele has been shown
to increase the risk of CAD in an Asian Indian sample
(Sanghera et al. 1998a). However, in the present study,
we found that the PON2 Cys311 allele was associated
with CAD risk. The frequencies of both the Cys allele
(0.293 vs. 0.219; ) and the Cys/Cys genotypePp .06
(15.2% vs. 4.6%; ) were higher in the groupPp .018
with three-vessel disease than in the groups with one-
vessel or two-vessel disease. The adjusted OR for the
PON2 codon 311 Cys/Cys genotype was 3.68 (95% CI
1.26–10.68; ) for the development of three-ves-Pp .017
sel disease. Additional functional studies with the PON2
Ser311Cys allelic isoformsmay help to determine the role
that this polymorphism plays in the etiology of CAD.
Like PON1 and PON3, PON2 also prevents LDL oxida-
tion (Ng et al. 2001). However, unlike PON1 and PON3,
PON2 is not associated with HDL and may exert its
antioxidant function at the cellular level. The present
study is the first study to show that the PON1 codon
192 Arg/Arg and PON2 codon 311 Cys/Cys genotypes
are significantly associated with CAD severity in terms
of the number of diseased vessels but not in terms of
stenosis severity. We could hypothesize that PON1 and
PON2 are not involved directly in the early stage of ste-
nosis development but instead are involved in the late
stage of multivessel-disease development. This hypoth-
esis may also explain some of the inconsistent results
in previously reported case-control studies, especially
for the PON1 polymorphisms. If this hypothesis is true,
because the patients/case subjects included in each re-
ported study may vary with regard to disease severity,
those studies including patients with more severe CAD
(i.e., having multiple vessels with50% stenosis)would
detect a stronger association than those with fewer se-
verely affected patients. Alternatively, LDL oxidation
and HDL-associated PON protective action affect all
stages of atherosclerosis, and the lack of association
with the single-vessel and double-vessel disease in the
present study may be due to the complex nature of
atherosclerosis. However, detailed functional data on
PON1 and PON2 would be essential, to verify whether
these two genes are involved in the early or late stage
of CAD development.
The results of the haplotype analyses were consistent
with the single-site analyses and also showed significant
association with CAD severity and PON haplotypes
( ). Since all three genes (PON1, PON2, andPp .012
PON3) are linked on chromosome 7, a detailed char-
acterization of the structure-function relationship of
PON mutations would be helpful in elucidating their
biological mechanisms in CAD.
The analyses of the interactions among the three
genotypes and the genotype-biological factors might
further support the hypothesis that PON1 codon 192
and PON2 codon 311 have functional effects on risk of
CAD. For example, we found an interaction ( )Pp .05
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between PON1 codon 192 genotype and BMI in affect-
ing the risk of CAD. This result suggests that the effect
that the PON1 codon 192 polymorphism has on the risk
of CAD may differ among groups with high or low BMI
levels. Because obesity ( ) is a significant riskBMI 1 30
factor for coronary disease (Al Suwaidi et al. 2001), this
result is logical, although additional analyses will be
needed to understand the mechanism of this possible in-
teraction. We also observed an interaction between the
PON2 codon 311 polymorphism and HDL cholesterol.
By itself, the PON2 codon 311 polymorphism was as-
sociated with an increased risk of CAD (OR 4.26). How-
ever, by the inclusion of an interaction with HDL cho-
lesterol, which is inversely associated with CAD risk
(Gordon et al. 1989), the PON2 codon 311 polymor-
phism was associated with decreased risk of CAD (OR
0.93). This result indicates that the association between
the PON2 codon 311 polymorphism and CAD risk may
differ among specific population subgroups (e.g., indi-
viduals with low versus high HDL-cholesterol levels).
However, because of the fairly large number of compar-
isons ( ) that we did in the interaction analyses,np 27
these two marginally significant interactions are provi-
sional and will need to be replicated in additional studies.
In summary, results of our analyses of data in the
WISE cohort suggest that common genetic variation
in the PON gene cluster may affect the risk of CAD,
especially the risk for development of severe CAD in
women. Our finding that the PON polymorphisms
may affect the severity of the disease may explain the
inconsistent published reports in which the relation-
ship between PON polymorphisms and CAD severity
has not been examined.
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